Voyager Therapeutics Inc. (VYGR) Trading 5.9% Higher
Voyager Therapeutics Inc. (NASDAQ:VYGR) shares traded up 5.9% on Thursday . The company traded as high as $15.17 and last traded at $15.11, with a volume of 52,890 shares changing hands. The stock had previously closed at $14.27.
A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 14th. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Wednesday, June 22nd. Finally, Stifel Nicolaus initiated coverage on shares of Voyager Therapeutics in a research note on Thursday, July 14th. They set a “buy” rating and a $33.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $30.25.
The stock’s market capitalization is $404.18 million. The company has a 50-day moving average of $12.77 and a 200-day moving average of $11.58.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Thursday, May 12th. The company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.67. On average, equities research analysts anticipate that Voyager Therapeutics Inc. will post ($1.46) EPS for the current fiscal year.
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.